The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies

The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies

BackgroundAltered gut microbiome (GM) composition has been established in Parkinson’s disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies.ObjectivesTo investigate the temporal stability of GM profiles from PD patients on standa...

Full description

Bibliographic Details
Main Authors:	Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Aging Neuroscience
Subjects:	gut microbiota gastrointestinal microbiome longitudinal progression device-assisted therapies levodopa-carbidopa intestinal gel
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2022.875261/full

Similar Items

Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease
by: Michal Lubomski, et al.
Published: (2022-05-01)

091 The impact of device-assisted therapy initiation on the gut microbiome in Parkinson’s disease
by: Michal Lubomski, et al.
Published: (2021-08-01)

037 The gut microbiome in Parkinson’s disease: longitudinal insights into disease progression and the use of device-assisted therapies
by: Michal Lubomski, et al.
Published: (2021-08-01)

LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
by: Walaa A. Kamel, et al.
Published: (2020-09-01)

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
by: Rajesh Pahwa, et al.
Published: (2023-01-01)

015 Gut microbiota and nutritional profiles of Parkinson’s disease patients
by: Michal Lubomski, et al.
Published: (2021-08-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

NEMoE: a nutrition aware regularized mixture of experts model to identify heterogeneous diet-microbiome-host health interactions
by: Xiangnan Xu, et al.
Published: (2023-03-01)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
by: Szász JA, et al.
Published: (2019-11-01)

Levodopa-Carbidopa Intestinal Gel Improves Symptoms of Orthostatic Hypotension in Patients with Parkinson’s Disease—Prospective Pilot Interventional Study
by: Simona Stanková, et al.
Published: (2022-04-01)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
by: Sten-Magnus Aquilonius, et al.
Published: (2017-04-01)

Increased Added Sugar Consumption Is Common in Parkinson's Disease
by: Natalie C. Palavra, et al.
Published: (2021-05-01)

Exploring Parkinson’s disease: A question and answer-based approach
by: Philippe Rizek, et al.
Published: (2018-01-01)

Effect of daidzein on Parkinson disease induced by reserpine in rats
by: Radha Goel, et al.
Published: (2020-04-01)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

An updated calculator for determining levodopa-equivalent dose
by: D. Nyholm, et al.
Published: (2021-10-01)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
by: Saki Oshiro, et al.
Published: (2021-12-01)

Health-Related Quality of Life for Parkinson’s Disease Patients and Their Caregivers
by: Michal Lubomski, et al.
Published: (2021-01-01)

Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
by: Eric Freire-Alvarez, et al.
Published: (2024-02-01)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
by: Daniël van Poppelen, et al.
Published: (2021-06-01)

The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson’s Disease: A Mini-Review
by: Germaine Hiu-Fai Chan
Published: (2022-06-01)

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
by: Noriyuki Miyaue, et al.
Published: (2023-01-01)

Lo Nuevo ante la Enfermedad de Parkinson
by: Juan Mendoza Vega
Published: (1990-12-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
by: József Attila Szász, et al.
Published: (2021-06-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
by: Takayasu Mishima, et al.
Published: (2021-07-01)

Endoscopic Complications Are More Frequent in Levodopa–Carbidopa Intestinal Gel Treatment via JET-PEG in Parkinson’s Disease Patients Compared to Nutritional PEG in Non-Parkinson’s Disease Patients
by: Laura Gombošová, et al.
Published: (2024-01-01)

Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis
by: Mihaela Adriana Simu, et al.
Published: (2021-11-01)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
by: Valentina Leta, et al.
Published: (2021-08-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study
by: Kanefumi Yamashita, et al.
Published: (2021-06-01)

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
by: Amnon A. Berger, et al.
Published: (2020-12-01)

Levodopa‐Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review
by: Atsushi Imamura, et al.
Published: (2023-11-01)

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
by: Victor S.C. Fung, et al.
Published: (2024-01-01)

Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients
by: Kensuke Ikenaka, et al.
Published: (2024-02-01)